Physician profile
Kyle Wayne Herbold
NPI 1568407013
$2,778.48
in general payments reported to CMS, 2019-2025
19 companies · $1,068 in 2025
The $1,068 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $149 · 2024: $1,561 · 2025: $1,068.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,531 · Education: $248.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,530.85 |
| Education | $247.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $545.89 | 2024-2025 | Taltz, Ebglyss, Olumiant |
| Janssen Biotech, INC. | $434.73 | 2023-2025 | Tremfya, Simponi, Stelara |
| Abbvie INC. | $409.05 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $243.20 | 2024-2025 | |
| Genzyme Corporation | $226.82 | 2024-2025 | |
| Incyte Corporation | $142.87 | 2024-2025 | Opzelura |
| Pfizer INC. | $116.65 | 2023-2025 | |
| Leo Pharma INC. | $107.56 | 2024-2025 | Adbry, Anzupgo |
| Sun Pharmaceutical Industries INC. | $101.18 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $100.45 | 2024-2025 | Dupixent, Libtayo |
| E.R. Squibb & Sons, L.L.C. | $77.81 | 2024-2025 | Sotyktu |
| Ucb, INC. | $51.67 | 2024-2025 | Bimzelx |
| Almirall LLC | $51.16 | 2024-2025 | Klisyri |
| Dermavant Sciences, INC. | $43.06 | 2024 | Vtama |
| Organon LLC | $35.86 | 2025 | Nexplanon, Vtama |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $25.90 | 2025 | Otezla |
| Verrica Pharmaceuticals INC. | $24.84 | 2025 | Ycanth |
| Paratek Pharmaceuticals, INC. | $20.01 | 2024 | Nuzyra |
| Biofrontera INC. | $19.77 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Herbold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.